News

Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes. Sales for the quarter rose 13% on a reported basis and 4.8% on a comparable basis. Danaher Corporation’s (NYSE:DHR) […]

SCHD charges just 0.06% per year, but taxable investors who lived through the March reconstitution discovered a second bill arriving in a very different form. Here is what the expense ratio line was never designed to show you.

Abbott Laboratories has shed billions in market value this year while the broader market climbed, yet one analyst on Wall Street sees a dramatically different story unfolding beneath the surface of the company's bruised financials.

Abbott Laboratories stock has fallen about 15% over the past year, yet a Discounted Cash Flow (DCF) intrinsic value estimate still points to meaningful upside compared with where the shares currently trade. At the same time, the broader valuation checks and market multiples suggest a picture that is closer to fair than clearly cheap. Over the past 12 months, Abbott Laboratories shares are down about 15%, which raises the question of whether recent weakness has already priced in key...

Facing competition from Edwards, Abbott is studying TriClip’s real-world safety and performance in about 1,000 patients.

Abbott Laboratories, Taiwan Semiconductor, and Johnson & Johnson have all delivered strong earnings releases in the Q2 cycle, with each breaking records while also lifting their outlooks.

AllianceBernstein (NYSE:AB) reported record assets under management and its strongest quarterly sales in five years during the second quarter of 2026, as fixed-income demand, private-market deployments and insurance-related mandates helped the firm return to positive organic growth. Adjusted earnin

ABT is expanding across diabetes care, oncology diagnostics and heart devices, with new launches and acquisitions creating multiple growth paths to watch.

Abbott Laboratories (NYSE:ABT) has secured exclusive U.S. commercialization rights for Freenome's SimpleScreen CRC, a newly FDA approved blood based colorectal cancer screening test. The approval and commercialization arrangement introduces a new screening option for eligible U.S. patients under current colorectal cancer testing guidelines. This agreement expands Abbott's presence in the colorectal cancer screening category within its broader diagnostics portfolio. For investors watching...

Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes. Sales for the quarter rose 13% on a reported basis and 4.8% on a comparable basis. Let’s dive deeper […]

Abbott will market Freenome’s SimpleScreen CRC test in the U.S., alongside its Cologuard stool test. SimpleScreen will compete with Guardant Health’s Shield blood test for colorectal cancer screening.

Jensen Investment Management, an asset management company based in the US, released its second-quarter 2026 investor letter for the “Jensen Quality Growth Equity Strategy”. A copy of the letter is available to download here. The fund seeks long-term growth by investing in high-quality companies with durable competitive advantages. It returned 10.94% net of fees in […]

ABT's earnings beat and higher profit outlook strengthen its case, but can growth in devices and diagnostics overcome valuation and acquisition concerns?

GM, ABT and JNJ stand out this earnings season after raising guidance, boosting outlooks and reinforcing momentum with stronger-than-expected quarterly results.

AbbVie has an attractive 2.7% yield, a solid pharmaceutical business, and is clearly focused on its dividend.

Device makers with cash flow yields of 5% to 6% now trade at a 20% to 30% discount to the S&P 500 index.

Danaher's latest earnings call saw analysts repeatedly test one sore spot in an otherwise solid quarter, and management's answers reveal the key risk for investors now.

ISRG's expanding robotic surgery ecosystem and innovation pipeline give it an edge over Abbott for investors seeking stronger long-term MedTech growth.

Abbott Laboratories earnings put recent stock moves in context Abbott Laboratories (ABT) is back in focus after its latest quarterly earnings, where higher year over year sales came alongside lower net income and earnings per share, sharpening attention on upcoming estimates. See our latest analysis for Abbott Laboratories. After these earnings, Abbott Laboratories' recent rally stands out, with a 7 day share price return of 12.66% and a 30 day share price return of 14.51% contrasting with a...

The market is offering a steep discount on this medical device maker, but the price tag comes with a story about slowing growth. Here’s how to read it.

JNJ is pruning its portfolio while Abbott just dropped $21 billion to expand into cancer diagnostics, and the two strategies are pulling their stocks in completely opposite directions. Which move looks smarter when you dig into the actual earnings?

BSX faces Q2 results with growth expected in key businesses, but lowered full-year guidance, cost pressures and weak stock performance cloud the outlook.

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Abbott's diversified healthcare business is one of the main reasons why it remains a reliable dividend stock.

Charles River Laboratories is poised to announce its second-quarter results next month, and analysts predict a double-digit drop in the company’s bottom-line figure.

Prosecutors have declined to charge businesses in a number of recent cases—despite believing that senior employees were involved in wrongdoing.

The healthcare giant's stock jump was about more than an earnings beat, offering proof of a growth story broader and more resilient than you thought.

Abbott Laboratories (ABT) beat Q2 expectations, with growth acceleration in the second half of 2026

Abbott's raised 2026 earnings outlook and four growth drivers point to a faster second half across nutrition, devices, diagnostics and diabetes care.

This healthcare giant is forecasting a significant acceleration, but you are being asked to look past a slowdown in its biggest growth engine and other execution hurdles.